AR102781A1 - Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos - Google Patents
Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usosInfo
- Publication number
- AR102781A1 AR102781A1 ARP150103849A ARP150103849A AR102781A1 AR 102781 A1 AR102781 A1 AR 102781A1 AR P150103849 A ARP150103849 A AR P150103849A AR P150103849 A ARP150103849 A AR P150103849A AR 102781 A1 AR102781 A1 AR 102781A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticles
- compound
- biocompatible
- pharmaceutical composition
- interest
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 19
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052710 silicon Inorganic materials 0.000 abstract 2
- 239000010703 silicon Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 239000011147 inorganic material Substances 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 abstract 1
- HDMKAUUMGFGBRJ-UHFFFAOYSA-N iron;dihydrate Chemical compound O.O.[Fe] HDMKAUUMGFGBRJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306874 | 2014-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102781A1 true AR102781A1 (es) | 2017-03-22 |
Family
ID=52013981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103849A AR102781A1 (es) | 2014-11-25 | 2015-11-24 | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10391058B2 (enExample) |
| EP (1) | EP3229776B1 (enExample) |
| JP (1) | JP6836510B2 (enExample) |
| AR (1) | AR102781A1 (enExample) |
| DK (1) | DK3229776T3 (enExample) |
| ES (1) | ES2951598T3 (enExample) |
| FI (1) | FI3229776T3 (enExample) |
| HU (1) | HUE062561T2 (enExample) |
| LT (1) | LT3229776T (enExample) |
| PL (1) | PL3229776T3 (enExample) |
| PT (1) | PT3229776T (enExample) |
| TW (1) | TW201628654A (enExample) |
| WO (1) | WO2016083343A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2948179T3 (pl) | 2013-01-25 | 2019-10-31 | Nanobiotix | Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu |
| MA38687A1 (fr) * | 2013-05-30 | 2017-12-29 | Nanobiotix | Composition pharmaceutique, préparation et utilisations de celle-ci |
| AU2015352685B2 (en) * | 2014-11-25 | 2020-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PT3229776T (pt) * | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
| DK3223796T3 (da) | 2014-11-25 | 2021-09-27 | Curadigm Sas | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf |
| PL3229843T3 (pl) | 2014-11-25 | 2020-06-29 | Curadigm Sas | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
| JP2018516256A (ja) | 2015-05-28 | 2018-06-21 | ナノビオティックスＮａｎｏｂｉｏｔｉｘ | 治療用ワクチンとしての使用のためのナノ粒子 |
| CN115137822B (zh) * | 2022-06-13 | 2023-06-23 | 武汉大学中南医院 | 一种光热热电一体化的抗肿瘤植入体的制备方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| AU4821697A (en) | 1996-10-18 | 1998-05-15 | Wayne State University | 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| DE69819519T2 (de) | 1997-08-19 | 2004-09-23 | Warner-Lambert Co. Llc | Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| EP1299085B1 (en) * | 2000-06-30 | 2005-11-16 | Inex Pharmaceuticals Corp. | Improved liposomal camptothecins and uses thereof |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| CA2547024C (en) | 2003-12-22 | 2013-12-17 | Bracco Research Sa | Gas-filled microvesicle assembly for contrast imaging |
| WO2005086639A2 (en) | 2004-02-10 | 2005-09-22 | Barnes-Jewish Hospital | Improved efficacy and safety of targeted particulate agents with decoy systems |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| US20070088414A1 (en) * | 2005-05-25 | 2007-04-19 | Campbell Robert L | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| WO2007122956A1 (ja) * | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| JP2009536151A (ja) | 2006-03-30 | 2009-10-08 | 富士フイルム株式会社 | ナノ粒子 |
| EP1852107A1 (en) | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| JP2009536162A (ja) | 2006-05-04 | 2009-10-08 | ユニバーシティー オブ サウス オーストラリア | ナノ粒子被覆カプセルからの薬物放出 |
| CA2697042A1 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| WO2009081287A2 (en) | 2007-12-21 | 2009-07-02 | University Of Guelph | Polysaccharide nanoparticles |
| CA2716347C (en) | 2008-02-21 | 2017-06-20 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) * | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| US20130023714A1 (en) | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| WO2012051220A1 (en) | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| RU2013117288A (ru) | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА |
| CN103429227B (zh) | 2011-01-31 | 2017-12-19 | 纳米生物技术公司 | 纳米粒子递送系统、其制备及应用 |
| EP2670393B8 (en) * | 2011-01-31 | 2016-10-05 | Nanobiotix | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles. |
| WO2013059295A2 (en) | 2011-10-17 | 2013-04-25 | Trustees Of Boston University | Polymeric depots for localization of an agent to biological sites |
| CN102532154B (zh) | 2012-01-11 | 2014-05-14 | 昆明医学院 | 隆萼当归线型呋喃香豆素化合物及其应用 |
| WO2014039874A2 (en) | 2012-09-07 | 2014-03-13 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| MA38687A1 (fr) | 2013-05-30 | 2017-12-29 | Nanobiotix | Composition pharmaceutique, préparation et utilisations de celle-ci |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| AU2015352685B2 (en) | 2014-11-25 | 2020-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PL3229843T3 (pl) | 2014-11-25 | 2020-06-29 | Curadigm Sas | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
| DK3223796T3 (da) | 2014-11-25 | 2021-09-27 | Curadigm Sas | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf |
| WO2016083336A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| PT3229776T (pt) * | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
-
2015
- 2015-11-24 PT PT158007773T patent/PT3229776T/pt unknown
- 2015-11-24 HU HUE15800777A patent/HUE062561T2/hu unknown
- 2015-11-24 EP EP15800777.3A patent/EP3229776B1/en active Active
- 2015-11-24 FI FIEP15800777.3T patent/FI3229776T3/fi active
- 2015-11-24 AR ARP150103849A patent/AR102781A1/es unknown
- 2015-11-24 LT LTEPPCT/EP2015/077446T patent/LT3229776T/lt unknown
- 2015-11-24 PL PL15800777.3T patent/PL3229776T3/pl unknown
- 2015-11-24 JP JP2017546034A patent/JP6836510B2/ja active Active
- 2015-11-24 ES ES15800777T patent/ES2951598T3/es active Active
- 2015-11-24 TW TW104139005A patent/TW201628654A/zh unknown
- 2015-11-24 WO PCT/EP2015/077446 patent/WO2016083343A1/en not_active Ceased
- 2015-11-24 DK DK15800777.3T patent/DK3229776T3/da active
- 2015-11-24 US US15/529,101 patent/US10391058B2/en active Active
-
2019
- 2019-08-26 US US16/550,342 patent/US11471410B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062561T2 (hu) | 2023-11-28 |
| US20190374465A1 (en) | 2019-12-12 |
| EP3229776A1 (en) | 2017-10-18 |
| PT3229776T (pt) | 2023-08-17 |
| US20170258717A1 (en) | 2017-09-14 |
| ES2951598T3 (es) | 2023-10-23 |
| PL3229776T3 (pl) | 2023-11-06 |
| EP3229776B1 (en) | 2023-06-28 |
| FI3229776T3 (fi) | 2023-08-15 |
| US10391058B2 (en) | 2019-08-27 |
| DK3229776T3 (da) | 2023-07-31 |
| JP6836510B2 (ja) | 2021-03-03 |
| TW201628654A (zh) | 2016-08-16 |
| WO2016083343A1 (en) | 2016-06-02 |
| JP2018504450A (ja) | 2018-02-15 |
| LT3229776T (lt) | 2023-08-25 |
| US11471410B2 (en) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
| WO2016011284A3 (en) | Methods and compositions comprising particles for use in oil and/or gas wells | |
| MX2020001155A (es) | Minerales que contienen carbonato de calcio de superficie modificada y su uso. | |
| AR102782A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| MX2017009948A (es) | Adsorbentes zeoliticos de alta superficie externa, su procedimiento de preparacion y sus usos. | |
| MX394658B (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos | |
| CL2016002258A1 (es) | Una composición para el cuidado oral que comprende un carbonato de calcio tratado mediante reacción superficial | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| CL2012003540A1 (es) | Compuestos derivados de triazolopiridinas sustituidas; metodo de preparacion; compuestos intermediarios; composicion farmaceutica que los comprende; uso del compuesto para la profilaxis o el tratamiento de leucemia, linfomas malignos, tumores de cabeza y cuello, tumores del torax, tumores gastrointestinales, entre otros. | |
| WO2017132555A8 (en) | Alk polypeptides and methods of use thereof | |
| WO2016059020A3 (en) | Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| JP2018504450A5 (enExample) | ||
| MX2017002029A (es) | Composiciones de profarmacos de aripiprazol. | |
| ITUB20160159A1 (it) | Composizione contenente grafene e nano piastrine grafeniche e loro procedimento di preparazione. | |
| MX391458B (es) | Carbonato de calcio precipitado, un metodo para su fabricacion y usos del mismo. | |
| WO2019103875A3 (en) | Methods of using and compositions containing dulaglutide | |
| MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
| WO2016015055A8 (en) | Colon cleansing compositions | |
| WO2016033549A3 (en) | (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | |
| CL2017003350A1 (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| CL2015003535A1 (es) | Composiciones farmacéuticas. | |
| CY1121594T1 (el) | Συνθεσεις προφαρμακου αριπιπραζολης | |
| ZA201901907B (en) | Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles | |
| HK40010656A (zh) | 非聚集固体颗粒形式的包含两种不同类型颗粒的快速摄入且便於吞咽的固体组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |